Drugs futures 2025? Perspective of the pharmaceutical industry

Drugs and the Future

Volumn , Issue , 2007, Pages 507-533

  Ragan, Ian ^a  

^a CIR Consulting Ltd ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866423869     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370624-9/50021-9     Document Type: Chapter

References (24)

1. BMJ Editorial: Suicide, depression, and antidepressants. BMJ 2005, 330:373-374.
2. A comprehensive assessment of the decliming drug development performance of the US pharmaceutical industry 2004, Boston Consulting Group.
3. Connecting Brains and Society 2004, The King Baudouin Foundation and the Rathenau Institute.
4. Evan W.E., Relling M.V. Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429:464-468.
5. IBM Business Consulting Services Pharma 2010: The threshold of innovation 2002.
6. Innovation in the pharmaceutical sector. A study undertaken for the European Commission by Charles River Associates. November 2004.
7. Kreek M.J., LaForge K.S., Butelman E. Pharmacotherapy of addictions. Nature Rev Drug Disc 2002, 1:710-725.
8. Lehman Brothers Pharma Pipelines 2003.
9. Lingford-Hughes A.R., Welch S., Nutt D.J. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. Psychopharmacol 2004, 18(3):293-335.
10. Little S. Curr Drug Disc 2004, 25-27.
11. Lynch G. Memory enhancement: the search for mechanism-based drugs. Nature Neurosci 2002, 5(Suppl):1035-1038.
12. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm 2003, 9(6):559-568.
13. Olesen J., Leonardi M. The burden of brain diseases in Europe. Eur J Neurology 2003, 10:471-477.
14. PharmaFutures The pharmaceutical sector. Along-term value outlook. December 2004.
15. Ralston G.E., Taylor J.A. Temazepam abuse. Addiction 1993, 88(3):423.
16. Ranga K., Krishnan R. Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psych 2002, 63(Suppl 11):25-29.
17. Roth L.R., Sheffler D.J., Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev Drug Disc 2004, 3:353-358.
18. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Substance P antagonists: meet the new drugs, same as the old drugs? Insights from transgenic animal models. Science 2003, 301:805-809.
19. Tufts Center for the Study of Drug Development Impact Report 2003, 5(3).
20. Tufts Center for the Study of Drug Development News release 29 April 2004.
21. Tully T., Bourtchouladze R., Scott R., Tallman J. Targeting the CREB pathway for memory enhancers. Nature Rev Drug Disc 2003, 2:267-277.
22. Volkow N.D., Li T.K. Drug addiction: the neurobiology of behavior gone away. Nature Rev Neurosci 2004, 5:963-970.
23. Wong M.-L., Licino J. From monoamines to generic targets: a paradigm shift for drug discovery in depression. Nature Rev Drug Disc 2004, 3:136-151.
24. Woolf C.J. Pain: moving from symptoms control toward mechanism-specific pharmacologic management. Ann Inter Med 2004, 140(6):441-451.